



JPM (JP Morgan Healthcare Conference) 2026

January 12-16, 2026; San Francisco, CA; Resource Hub – Draft

Welcome to our resource hub for JPM 2026! This is a one-stop-shop for all your JPM needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Diabetes Technology Highlights](#)

[Big Picture Highlights](#)

[Previous JPM Coverage on CCKB](#)

Useful Conference Links

1. [Conference Website](#)
2. [Conference Agenda](#)
3. [Day-by-Day Conference Preview](#)

Day-of Conference Reports

1. [JPM 2026 Day #1 Highlights](#)
2. [JPM 2026 Day #2 Highlights](#)
3. [JPM 2026 Day #3 Highlights](#)
4. [JPM 2026 Day #4 Highlights](#)

Diabetes Therapy Highlights

1. [Roche: Targeting a “top three” role in obesity](#) through petrelintide, pegozafermin, and more; anti-VEGF Vabysmo returns to growth after market challenges
2. [Pfizer: Dr. Albert Bourla shares vision of obesity treatment landscape](#) with Metsera’s assets and reflects on MFN and tariffs
3. [Amgen: PCSK-9 inhibitor Repatha highlighted as key](#) to Amgen’s growth through 2030; extensive discussion of long-acting T2D and obesity candidate MariTide
4. [Merck: “Democratizing” PCSK9 therapy and combinations with Lp\(a\)](#); MK 3000 as a potential new mechanism of action for diabetic macular edema
5. [Sanofi: Strategies and progress](#) across mid- to late-stage development projects; teplizumab receives approval in the EU for stage 2 T1D
6. [Regeneron: CEO Dr. Leonard Schleifer and CSO Dr. George Yancopoulos](#) emphasize internal R&D engine, Eylea HD momentum, and obesity strategy
7. [Viking: Dr. Brian Lian highlights oral and injectable VK2735](#) (dual GLP-1/GIP RA) and amylin agonist for obesity
8. [J&J: CEO Mr. Joaquin Duato outlines diversified growth strategy](#) with momentum in cardiovascular portfolio

9. [Madrigal: “10% of 10%” of global MASH patients treated](#); detailed approaches to combination therapy, including GLP-1 RAs and DGAT-2 inhibitors
10. [Arrowhead Pharmaceuticals: RNA interference treatments](#) for obesity to advance to phase 2b trial
11. [Corcept Therapeutics: Dr. Joseph Belanoff highlights the broad implications of cortisol modulation](#), including hypercortisolism, obesity, and diabetes
12. [Novartis: De-risked pipeline driving post-Entresto growth](#); Leqvio as the foundational therapy for the company’s cardiorenal metabolic franchise
13. [Vertex: Journavx \(suzetrigine\) shows strong growth in the pain sector](#) with potential indication for diabetic peripheral neuropathy
14. [Lilly](#): Mr. David Ricks shares insights about obesity market, payment channels, and clinical pipeline including orforglipron
15. [Novo Nordisk](#): Mr. Mike Doustdar on mastering cash channel, reframing perception of the semaglutide, and clinical pipeline with CagriSema, cagrilintide, and amycretin
16. [Teva Pharmaceuticals](#): Teva to shift from generics firm to global biopharmaceutical company
17. [AstraZeneca](#): Cardiometabolic focus for 2030 and beyond led by aldosterone synthase inhibitor baxdrostat, PCSK-9 laroprovstat, and GLP-1 RAs in development
18. [Kailera Therapeutics](#): CEO Mr. Ron Renaud highlights diversified GLP-1 RA pipeline for obesity treatment
19. [Bayer](#): Kerendia (finerenone) demonstrates blockbuster potential for CKD and heart failure; pricing pressures with Eylea (afibercept)
20. [Ionis Pharmaceuticals](#): Tryngolza gains traction in treatment of FCS ahead of broader launch; pelacarsen for Lp(a) risk reduction on track for launch in 2027
21. [Zealand Pharma: Dr. Adam Steensberg highlights survodutide and petrelintide](#); clinical data expected in 2026
22. [Amphastar: Dr. Jack Zhang shares updates](#) on glucagon, GLP-1 RAs, and insulin biosimilars
23. [Sana Biotechnology: Continuing strides for allogeneic islet cell therapy](#) with developed with hypimmune technology in people with T1D
24. [Biomea Fusion: Phase 2 data for Icovamenib](#) and phase 1 results of GLP-1 RA BMF-650 expected in 2026
25. [AbbVie: Interest in entering obesity arena by leveraging familiarity](#) with cash-pay channel and compounding market
26. [Lexicon Pharmaceuticals](#): Dr. Mike Exton highlights SGLT-1/2 inhibitor sotagliflozin, pilavapadin for DPN, and non-incretin obesity candidate
27. [SAB Bio: Mr. Samuel Reich on differentiating features of SAB-142](#) as a disease modifying therapy for T1D
28. [Esperion: Updated US lipid-lowering guidelines](#) to include bempedoic acid offering; international expansions; combination therapy
29. [Biocon: Addressing global non-communicable diseases like diabetes](#); generics and biosimilar business restructuring

Diabetes Technology Highlights

1. [Dexcom: Preliminary full-year 2025 revenue of \\$4.66 billion \(+16%\)](#) and 4Q25 revenue of \$1.26 billion (+13%); global userbase grows over 25% to 3.5 million
2. [Medtronic: With Diabetes business spinoff expected by the end of 2026](#), management highlights four new generational growth platforms
3. [Insulet: CEO Ms. Ashley McEvoy highlights growth opportunity](#) across US T1D, US T2D, and OUS T1D; robust innovation pipeline through 2028
4. [Verily: Progress on Verily Pre for clinical research facilitation](#) and Verily Me for telehealth

5. [Omada Health: Preliminary full-year 2025 revenue of ~\\$257 million \(+52%\)](#); 2026 will see investment in GLP-1 RA Care Track and AI tools
6. [embecta: GLP-1 RAs offer >\\$100 million annual opportunity](#); “market-appropriate” products for China and other geographies
7. [Virta Health: Tailwinds from GLP-1 RAs](#); combining the platform with pharmacotherapy for sustained weight loss and metabolic benefit
8. [Ypsomed: CFO Mr. Samuel Künzli reviews product launches](#) and global manufacturing expansion in 2025; one billion unit manufacturing capacity targeted for 2030

Big Picture Highlights

1. [JPM’s Jeremy Meilman welcomes over 9,000 attendees](#), reflecting on four decades of global health industry
2. [San Francisco Mayor Mr. Daniel Lurie](#) welcomes business, scientific, and medical leaders to San Francisco
3. [CMS comes to SF: Dr. Mehmet Oz and CMS leadership](#) discuss GLP-1 RAs, long-term health, MFN, and MAHA
4. [The FDA’s Dr. Marty Makary on optimized regulation](#), accelerating the 12-year approval timeline, and additives in our food supply
5. [From agentic AI to longevity](#): ARPA-H’s strategy for breakthrough health innovation
6. [Employer coverage at crossroads](#): Managing GLP-1 RAs and breakthrough therapies
7. [Technology and strategy](#) to capture Asia’s growing patient markets
8. [The growing strength of Chinese biotechnology](#): Gaining trust and partnership

Previous JPM Coverage on CCKB

1. [JPM 2025 Resource Hub](#)
2. [JPM 2024 Resource Hub](#)
3. [JPM 2023 Resource Hub](#)
4. [JPM 2022 Resource Hub](#)
5. [JPM 2021 Resource Hub](#)